Group 1 - The company held its 22nd meeting of the 4th Board of Directors on August 1, 2025, with all 7 participating directors voting unanimously [1] - The Board approved the proposal not to lower the conversion price of the "Jietai Convertible Bonds," with 4 votes in favor and no opposition or abstentions [1] - Related directors recused themselves from the voting process [1] Group 2 - The company will not propose a downward adjustment to the conversion price within the next three months, from now until November 1, 2025 [2] - If the conversion price adjustment clause is triggered again after November 2, 2025, the Board will reconvene to decide on the adjustment [2] - Further details are available in the announcement published on the Shanghai Stock Exchange website [2]

Core Viewpoint - The company, JieTe Bio, announced that its board of directors has approved a proposal not to lower the conversion price of its convertible bonds, known as "JieTe Convertible Bonds" [2] Group 1 - The fourth meeting of the fourth board of directors took place on August 1, where the proposal was reviewed and approved [2]

| 证券代码：688026 | 证券简称：洁特生物 | 公告编号：2025-048 | | --- | --- | --- | | 转债代码：118010 | 转债简称：洁特转债 | | 广州洁特生物过滤股份有限公司 关于不向下修正"洁特转债"转股价格的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 因公司实施 2024 年年度权益分派方案，"洁特转债"的转股价格自 2025 年 7 月 2 日起由 48.02 元/股调整为 47.95 元/股，具体内容详见公司于 2025 年 6 月 25 日披露的《关于实施 2024 年年度权益分派时调整"洁特转债"转股价格的公告》 （公告编号：2025-037）。 重要内容提示： 一、转股价格调整/修正依据 （一）"洁特转债"基本情况 经中国证券监督管理委员会《关于同意广州洁特生物过滤股份有限公司向不 特定对象发行可转换公司债券注册的批复》（证监许可〔2022〕432 号）同意注 册，广州洁特生物过滤股份有限公司（以下简称"公司"）向不特定对象共计发 行 440.00 万张，每 ...

| 证券代码：688026 | 证券简称：洁特生物 | 公告编号：2025-047 | | --- | --- | --- | | 转债代码：118010 | 转债简称：洁特转债 | | 广州洁特生物过滤股份有限公司 第四届董事会第二十二次会议决议公告 公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 广州洁特生物过滤股份有限公司（以下简称"公司"）第四届董事会第二十二 次会议于 2025 年 8 月 1 日以现场及通讯相结合方式召开，会议通知已于 2025 年 7 月 25 日通过通讯方式送达全体董事。本次会议由董事长袁建华先生召集并主 持，应参加董事 7 人，实际参加表决董事 7 人。本次会议的召集、召开和表决程 序均符合国家有关法律、法规及《公司章程》等有关规定。经全体董事一致同 意，形成决议如下： 一、以 4 票同意，0 票反对，0 票弃权，审议通过了《关于不向下修正"洁 特转债"转股价格的议案》，关联董事袁建华、Yuan Ye James、Dannie Yuan 回避表决。 董事会同意本次不向下修正转股价格，同时在未 ...

| 证券代码：688026 | 证券简称：洁特生物 | 公告编号：2025-046 | | --- | --- | --- | | 转债代码：118010 | 转债简称：洁特转债 | | 广州洁特生物过滤股份有限公司 关于"洁特转债"预计满足转股价格修正条件的 提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 可转债代码：118010 可转债简称：洁特转债 转股价格：47.95 元/股 转股期限：2023 年 1 月 4 日至 2028 年 6 月 27 日 经上海证券交易所自律监管决定书（[2022]203 号文）同意，公司 44,000.00 万元可转债于 2022 年 8 月 2 日起在上海证券交易所挂牌交易，债券简称"洁特 转债"，债券代码"118010"。 根据有关规定及《广州洁特生物过滤股份有限公司向不特定对象发行可转换 公司债券证券募集说明书》（以下简称"《募集说明书》"）的约定，公司本次发行 的"洁特转债"自 2023 年 1 月 4 日起可转换为公司股份，初始转股价格为 48.2 ...

Summary of Key Points Core Viewpoint - The announcement details the completion of a share reduction plan by a major shareholder of Guangzhou Jiete Biological Filtration Co., Ltd, indicating a strategic move in the company's ownership structure and potential implications for future governance and investment. Group 1: Shareholder Information - The shareholder, Guangzhou Luogang District Huizi Investment Management Partnership (Limited Partnership), held 1,396,950 shares, representing 1.00% of the company's total share capital prior to the reduction plan [2]. - The shares were acquired before the company's IPO and through capital reserve conversion, with the lock-up period lifted on January 30, 2023, allowing for trading [2]. Group 2: Reduction Plan Implementation - The shareholder planned to reduce holdings by up to 186,315 shares, which is 0.1327% of the total share capital, through centralized bidding [3]. - As of July 10, 2025, the shareholder successfully reduced their holdings by 186,315 shares, fully aligning with the previously disclosed reduction plan [3][4]. - The reduction was confirmed to have met the planned minimum reduction quantity, and the plan was not terminated early [4].

Summary of Key Points Core Viewpoint - The announcement details the completion of a share reduction plan by a major shareholder of Guangzhou Jiete Biological Filtration Co., Ltd, indicating a strategic move in the company's shareholder structure and potential implications for future stock performance [1][2]. Shareholder Holding Situation - Before the reduction plan, the shareholder Guangzhou Luogang District Huizi Investment Management Partnership (Limited Partnership) held 1,396,950 shares, accounting for 1.00% of the company's total share capital [1]. - The shares were acquired prior to the company's IPO and through capital reserve conversion, with the lock-up period lifted on January 30, 2023 [1]. Reduction Plan Implementation Results - As of July 10, 2025, the shareholder had reduced their holdings by 186,315 shares, representing 0.1327% of the total share capital [2]. - The reduction was executed through centralized bidding, with a total amount of approximately 3,098,815.23 yuan, at a price range of 16.49 to 16.85 yuan per share [2]. - Following the reduction, the shareholder's remaining shares totaled 1,210,635, which is 0.86% of the total share capital [2]. Consistency with Previous Disclosures - The actual reduction aligns with the previously disclosed reduction plan, confirming that the planned reduction was fully executed [2].

| 证券代码：688026 | 证券简称：洁特生物 | 公告编号：2025-045 | | --- | --- | --- | | 转债代码：118010 | 转债简称：洁特转债 | | 广州洁特生物过滤股份有限公司 股东减持股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 本次减持计划实施前，股东广州萝岗区汇资投资管理合伙企业（有限合伙） （以下简称"汇资投资"）持有广州洁特生物过滤股份有限公司（以下简称"公司"） 股份 1,396,950 股，占公司总股本 1.00%。上述股份来源为公司 IPO 前取得的及 通过资本公积转增股本取得的股份，已于 2023 年 1 月 30 日解除限售并上市流通。 减持计划的实施结果情况 公司于 2025 年 6 月 10 日披露了《股东减持股份计划公告》（公告编号： 2025-033）。汇资投资拟通过集中竞价方式减持股份数量不超过 186,315 股，占公 司总股本不超过 0.1327%。截至本公告日，汇资投资通过集中竞价交易方式已累 计减持 1 ...

Summary of Key Points Core Viewpoint - The company has established a special account for the management and use of raised funds, ensuring investor protection and compliance with regulatory requirements [1][2][3]. Fundraising Basic Information - The company issued 4.4 million convertible bonds at a face value of 100 RMB each, raising a total of 440 million RMB, which has been verified by Tianjian Accounting Firm [1]. Special Account Establishment - A special account for raised funds has been set up to temporarily supplement working capital, with a limit of 200 million RMB, effective for up to 12 months from December 30, 2024 [2][3]. Three-Party Supervision Agreement - The company signed a three-party supervision agreement with the underwriter and the bank to regulate the management of raised funds, ensuring they are used solely for designated purposes [3][4]. Regulatory Compliance - The agreement aligns with relevant laws and regulations, including the Shanghai Stock Exchange's self-regulatory guidelines, to protect investor rights [4][5]. Monitoring and Reporting - The underwriter is responsible for ongoing supervision of the fund usage, including site investigations and documentation requests, to ensure compliance with the agreement [4][5].

| 证券代码：688026 | 证券简称：洁特生物 公告编号：2025-044 | | --- | --- | | 转债代码：118010 | 转债简称：洁特转债 | 广州洁特生物过滤股份有限公司 关于增设募集资金专户并签署募集资金专户存储 三方监管协议的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、 募集资金基本情况 经中国证券监督管理委员会《关于同意广州洁特生物过滤股份有限公司向不 特定对象发行可转换公司债券注册的批复》（证监许可〔2022〕432 号）同意注 册，公司向不特定对象共计发行 440.00 万张，每张面值为人民币 100 元，按面 值发行。本次发行的募集资金总额为 440,000,000.00 元，扣除相关发行费用 7,508,492.65 元，实际募集资金净额 432,491,507.35 元。 上述募集资金已全部到位，并由天健会计师事务所（特殊普通合伙）于 2022 年 7 月 4 日对本次发行的资金到账情况进行了审验，出具了《广州洁特生物过滤 股份有限公司向不特定对象发行可转换公司债券募 ...